Sign in
IOVA Stock Price, Chart, Stats & News
Iovance Biotherapeutics, Inc.
Save
1.52B
Market cap
–
Current P/E
–
Forward P/E
IOVA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.23% |
Operating margin | -153.08% |
Pretax margin | -149.16% |
Net margin | -148.38% |
Effective tax rate | 0.53% |
ROA | -42.82% |
ROE | -54.54% |
D/E | 0.07x |
Interest coverage ratio | – |
IOVA valuation
P/E | – |
P/S | 4.42x |
P/B | 2.04x |
P/CF | -4.72x |
P/FCF | -3.46x |
P/OCF | -4.72x |
PEG | -0.40x |
EV multiple | -3.54x |
About
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials.
Similar securities
Based on sector and market capitalization
Report issue